Sponsor
Cory Anthony Booker
Senator · D-NJ
Senator · D-NJ
The bill extends emergency scheduling for fentanyl analogues to keep dangerous substances off the street and preserve law-enforcement and rapid-control tools, but it restricts research access and raises compliance and enforcement costs for institutions and taxpayers.
People at risk of accidental fentanyl exposure (e.g., people with substance use disorders and those in communities with high illicit fentanyl supply) face reduced short-term availability of some illicit fentanyl analogues because emergency scheduling remains in effect through Sept 30, 2025.
Law enforcement agencies retain scheduled-control tools for an additional six months, supporting continued prosecution and interdiction of fentanyl analogues.
Federal regulators keep the ability to accelerate controls without full rulemaking, preserving a rapid federal response to new fentanyl analogues.
Scientists and clinicians studying fentanyl analogues face greater hurdles because extended emergency scheduling limits research access and requires additional DEA approvals.
Hospitals, clinical labs, and manufacturers that handle controlled substances may face increased compliance costs and enforcement burdens while the emergency schedule remains in effect.
Taxpayers may bear additional federal costs for enforcement and regulatory administration associated with continuing the emergency scheduling for six more months.
Based on analysis of 2 sections of legislative text.
Extends the emergency scheduling end date for fentanyl-related substances from March 31, 2025 to September 30, 2025.
Extends the temporary emergency scheduling of fentanyl-related substances by moving the expiration date from March 31, 2025 to September 30, 2025. This keeps fentanyl-related substances subject to the current emergency controls for six more months while the longer-term regulatory or legislative process continues.
Introduced February 25, 2025 by Cory Anthony Booker · Last progress February 25, 2025